文献速递血栓与止血

血友病关节病的致病机制与新型实验性抗炎治疗

Pathogenic mechanisms and novel experimental anti-inflammatory therapies in hemophilic arthropathy.
PubMed 文献 · J Thromb Haemost · 2026-10-05

血友病关节病(HA)由反复关节出血引起,滑膜炎是驱动其进展的关键因素。临床前研究聚焦于靶向关节出血后激活的炎症通路,包括细胞因子和免疫细胞介导的信号网络。近期有限临床前研究提示,细胞外囊泡(EVs)可通过同时调控炎症、血管生成、血管功能障碍和软骨退变等多病理过程,减缓实验小鼠HA进展。

要点

  • 滑膜炎是血友病关节病进展的关键驱动因素,抗炎干预有望预防或限制关节恶化。
  • 临床前研究已识别多个可减轻疾病进展的治疗靶点,但疗效不一且受HA发病机制复杂性限制。
  • EVs具有多效生物活性且可工程化增强疗效和靶向性,可能成为延缓HA进展的新型辅助治疗。

核心结论

  • 滑膜炎是HA进展的关键驱动因素,抗炎干预是预防或限制关节 deterioration 的有前景策略。
  • EVs在实验小鼠模型中通过多效调控炎症、血管生成、血管功能障碍和软骨退变,展现治疗潜力。
  • 抗炎治疗仍主要处于临床前阶段,但越来越多证据支持其转化潜力。

研究设计与样本

  • 综述性文章,总结血友病关节病的致病机制及新型实验性抗炎治疗进展。
  • 引用近期临床前研究,聚焦关节出血后激活的炎症通路及EVs相关研究。

主要发现

  • 滑膜炎症促进滑膜增生、巨噬细胞浸润、病理性血管生成和软骨破坏。
  • 靶向细胞因子和免疫细胞介导的信号网络可减轻疾病进展,但疗效不一且受HA发病机制复杂性限制。
  • 有限临床前研究显示EVs在实验小鼠模型中通过同时调控多种病理过程减缓HA进展。

临床怎么用

  • 抗炎干预有望用于预防或限制出血发作后的关节恶化。
  • EVs可能成为延缓HA进展的新型辅助治疗,但尚需进一步转化研究。

局限性

  • 抗炎治疗仍主要处于临床前阶段,疗效不一且受HA发病机制复杂性限制。
  • EVs相关研究为有限临床前研究,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilic arthropathy (HA) is a chronic, progressive, and debilitating joint disorder resulting from recurrent hemarthroses in individuals with hemophilia. Despite major advances in prophylactic clotting factor replacement and the introduction of non-factor therapies that have markedly reduced bleeding frequency, HA remains a significant unmet clinical challenge. Accumulating evidence indicates that synovial inflammation is a key driver of HA progression, promoting synovial hyperplasia, macrophage infiltration, pathologic angiogenesis, and cartilage destruction. Consequently, anti-inflammatory interventions have emerged as a promising strategy to prevent or limit joint deterioration following bleeding episodes. Recent preclinical studies have focused on targeting inflammatory pathways activated after joint bleeding, including cytokine- and immune cell-mediated signaling networks. These investigations have identified several therapeutic targets that can attenuate disease progression, although their efficacy has been variable and often limited by the complexity of HA pathogenesis. More recently, limited preclinical studies suggest that extracellular vesicles (EVs) exhibit promising therapeutic potential in attenuating the progression of HA in experimental murine models by simultaneously modulating multiple pathologic processes, including inflammation, angiogenesis, vascular dysfunction, and cartilage degeneration. Unlike therapies directed against a single inflammatory mediator, EVs possess pleiotropic biological activities and can be engineered to enhance therapeutic efficacy and tissue targeting. Although anti-inflammatory therapies for HA remain largely in the preclinical stage, growing evidence supports their translation potential. Continued advances in EV biology, cargo engineering, manufacturing, and delivery technologies may establish EV-based therapeutics as a novel and effective adjunct to current treatment strategies for preventing or slowing HA progression.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kavadipula P, Rao LVM. Pathogenic mechanisms and novel experimental anti-inflammatory therapies in hemophilic arthropathy. J Thromb Haemost. 2026. PMID: 42833297. doi:10.1016/j.jtha.2026.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。